IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Curi RMB Capital LLC

Curi RMB Capital LLC lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 26.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,070 shares of the company’s stock after buying an additional 1,499 shares during the period. Curi RMB Capital LLC’s holdings in IDEXX Laboratories were worth $2,923,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Tidal Investments LLC raised its stake in shares of IDEXX Laboratories by 7.6% during the third quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock valued at $3,188,000 after purchasing an additional 444 shares during the period. Franklin Resources Inc. grew its holdings in IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after purchasing an additional 34,305 shares in the last quarter. American Trust purchased a new stake in IDEXX Laboratories during the 3rd quarter worth $757,000. Oddo BHF Asset Management Sas acquired a new position in IDEXX Laboratories in the 3rd quarter worth $1,128,000. Finally, GAMMA Investing LLC boosted its position in IDEXX Laboratories by 3.3% in the 4th quarter. GAMMA Investing LLC now owns 1,533 shares of the company’s stock valued at $634,000 after buying an additional 49 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 12th. Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research note on Monday, April 14th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $523.75.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 2.3 %

Shares of NASDAQ:IDXX opened at $411.72 on Monday. The company’s fifty day moving average is $422.37 and its two-hundred day moving average is $430.47. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The stock has a market capitalization of $33.37 billion, a price-to-earnings ratio of 38.59, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.